Metabolism of clenbuterol in rats. 1998

D Zalko, and L Debrauwer, and G Bories, and J Tulliez
Laboratoire des Xénobiotiques, Institut National de la Recherche Agronomique, Cedex, France.

The metabolic fate of [14C]clenbuterol was studied in male and female Wistar rats. After a single oral dose of 200 microgram/kg [14C]clenbuterol, in an 8-day study period, approximately 60% of the radioactivity was eliminated in urine; 20 and 30% of the radioactivity was excreted in feces by male and female rats, respectively. HPLC coupled to on-line radioactivity detection allowed the separation and quantitation of clenbuterol metabolites, some of which were found to be poorly stable in urine. Most of the urinary and fecal metabolites of clenbuterol were isolated and identified using various MS techniques. Analytical methods were also developed to establish the metabolic profiles in feces and tissues, up to 72 hr after clenbuterol administration. Clenbuterol was mainly metabolized by N-dealkylation (secondary amine), as well as N-oxidation and sulfate conjugation (primary amine). Gender-related differences in the rates of clenbuterol N-dealkylation were observed. 4-N-Hydroxylamine was the major metabolite detected in urine, whereas more than one half of the radioactivity in feces was associated with clenbuterol sulfamate.

UI MeSH Term Description Entries
D008297 Male Males
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D002976 Clenbuterol A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma. NAB-365,Planipart,NAB 365,NAB365
D005243 Feces Excrement from the INTESTINES, containing unabsorbed solids, waste products, secretions, and BACTERIA of the DIGESTIVE SYSTEM.
D005260 Female Females
D006868 Hydrolysis The process of cleaving a chemical compound by the addition of a molecule of water.
D000318 Adrenergic beta-Agonists Drugs that selectively bind to and activate beta-adrenergic receptors. Adrenergic beta-Receptor Agonists,beta-Adrenergic Agonists,beta-Adrenergic Receptor Agonists,Adrenergic beta-Agonist,Adrenergic beta-Receptor Agonist,Betamimetics,Receptor Agonists, beta-Adrenergic,Receptors Agonists, Adrenergic beta,beta-Adrenergic Agonist,beta-Adrenergic Receptor Agonist,Adrenergic beta Agonist,Adrenergic beta Agonists,Adrenergic beta Receptor Agonist,Adrenergic beta Receptor Agonists,Agonist, Adrenergic beta-Receptor,Agonist, beta-Adrenergic,Agonist, beta-Adrenergic Receptor,Agonists, Adrenergic beta-Receptor,Agonists, beta-Adrenergic,Agonists, beta-Adrenergic Receptor,Receptor Agonist, beta-Adrenergic,Receptor Agonists, beta Adrenergic,beta Adrenergic Agonist,beta Adrenergic Agonists,beta Adrenergic Receptor Agonist,beta Adrenergic Receptor Agonists,beta-Agonist, Adrenergic,beta-Agonists, Adrenergic,beta-Receptor Agonist, Adrenergic,beta-Receptor Agonists, Adrenergic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.
D014018 Tissue Distribution Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios. Distribution, Tissue,Distributions, Tissue,Tissue Distributions

Related Publications

D Zalko, and L Debrauwer, and G Bories, and J Tulliez
December 2002, Journal of applied physiology (Bethesda, Md. : 1985),
D Zalko, and L Debrauwer, and G Bories, and J Tulliez
May 2014, Biopharmaceutics & drug disposition,
D Zalko, and L Debrauwer, and G Bories, and J Tulliez
November 1993, Journal of animal science,
D Zalko, and L Debrauwer, and G Bories, and J Tulliez
February 1997, Journal of animal science,
D Zalko, and L Debrauwer, and G Bories, and J Tulliez
January 1991, Comparative biochemistry and physiology. A, Comparative physiology,
D Zalko, and L Debrauwer, and G Bories, and J Tulliez
January 1999, Diabetes, obesity & metabolism,
D Zalko, and L Debrauwer, and G Bories, and J Tulliez
February 1990, Physiology & behavior,
D Zalko, and L Debrauwer, and G Bories, and J Tulliez
December 1998, The Analyst,
D Zalko, and L Debrauwer, and G Bories, and J Tulliez
February 1988, Journal of animal science,
Copied contents to your clipboard!